Alvotech (ALVO) Long-Term Debt Repayments (2021 - 2026)
Alvotech's (ALVO) quarterly Long-Term Debt Repayments came in at -$9.0 million in Q1 2026, down 153.89% YoY from $16.8 million in Q1 2025, and down 216.89% on a QoQ basis from $7.7 million in Q3 2025.
Alvotech (ALVO) Long-Term Debt Repayments (2021 - 2026) Analysis & Trends
Alvotech (ALVO) has 6 years of Long-Term Debt Repayments data on file, last reported at -$9.0 million in Q1 2026.
- Quarterly Long-Term Debt Repayments fell 153.89% year-over-year to -$9.0 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$9.1 million (up 98.79% YoY) and the FY2023 annual result came in at -$99.4 million, down 463.84% from the prior year.
- Long-Term Debt Repayments eased to -$9.0 million in Q1 2026, from $7.7 million in the prior quarter.
- In the past five years, Long-Term Debt Repayments ranged from a high of $75.8 million in Q3 2024 to a low of -$749.1 million in Q4 2024.
- A 5-year average of -$81.3 million and a median of -$21.4 million in 2023 frame the typical range for Long-Term Debt Repayments.
- The widest YoY moves for Long-Term Debt Repayments: up 96.79% in 2024, down 653.85% in 2024.
- Tracing ALVO's Long-Term Debt Repayments over 5 years: stood at -$34.7 million in 2022, then slumped by 186.24% to -$99.4 million in 2023, then tumbled by 653.85% to -$749.1 million in 2024, then surged by 101.03% to $7.7 million in 2025, then sank by 216.89% to -$9.0 million in 2026.
- The last three Long-Term Debt Repayments figures came in at -$9.0 million (Q1 2026), $7.7 million (Q3 2025), and -$4.2 million (Q2 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Long-Term Debt Repayments (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 43.83 Bn | 42.86 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 42.87 Bn | 39.22 Bn | 2.15 Bn | - |
| 3 | Zoetis | 31.41 Bn | 29.73 Bn | 1.05 Bn | - |
| 4 | Takeda Pharmaceutical | 28.55 Bn | 22.75 Bn | 5.10 Bn | -156,847.56 |
| 5 | United Therapeutics | 22.08 Bn | 19.42 Bn | 683.80 Mn | - |
| 6 | Viatris | 18.73 Bn | 17.84 Bn | 1.46 Bn | - |
| 7 | Neurocrine Biosciences | 15.44 Bn | 15.05 Bn | 935.80 Mn | - |
| 8 | Elanco Animal Health | 11.75 Bn | 11.22 Bn | 798.00 Mn | - |
| 9 | Dr Reddys Laboratories | 10.11 Bn | 9.94 Bn | - | - |
| 10 | Alvotech | 1.26 Bn | 1.26 Bn | 5.09 Mn | -9.05 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -9.05 Mn |
| Mar 31, 2026 | -9.05 Mn |
| Sep 30, 2025 | 7.74 Mn |
| Sep 30, 2025 | 7.74 Mn |
| Jun 30, 2025 | -4.19 Mn |
| Jun 30, 2025 | -4.19 Mn |
| Mar 31, 2025 | -3.56 Mn |
| Mar 31, 2025 | -3.56 Mn |
| Dec 31, 2024 | -749.08 Mn |
| Dec 31, 2024 | -749.08 Mn |
| Sep 30, 2024 | 75.80 Mn |
| Sep 30, 2024 | 75.80 Mn |
| Jun 30, 2024 | -73.43 Mn |
| Jun 30, 2024 | -73.43 Mn |
| Mar 31, 2024 | -1.63 Mn |
| Mar 31, 2024 | -1.63 Mn |
| Dec 31, 2023 | -99.37 Mn |
| Dec 31, 2023 | -99.37 Mn |
| Jun 30, 2023 | -33.70 Mn |
| Jun 30, 2023 | -33.70 Mn |